• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: ASCENSIA DIABETES CARE US INC. CONTOUR® NEXT; QUALITY CONTROL MATERIAL

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

ASCENSIA DIABETES CARE US INC. CONTOUR® NEXT; QUALITY CONTROL MATERIAL Back to Search Results
Model Number 7314
Medical Device Problem Code Incorrect, Inadequate or Imprecise Result or Readings (1535)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 08/26/2025
Type of Reportable Event Malfunction
Additional Manufacturer Narrative
The patient/family (a1) was the initial reporter (e1), so personal information was not entered.No information was captured in sections a2 and a4 as the customer's age and weight were not provided.
 
Event or Problem Description
The customer called ascensia customer service to seek assistance with the contour® next gen meter.During troubleshooting, a control test was run and a reading of 186 mg/dl at 4:34 p.M.Was obtained.The meter did not automatically mark it as a control test, and so the reading will be displayed as a blood result when accessing the meter's memory.There was no allegation of an adverse event.The customer refused to return the suspected device for evaluation.
 
Additional Manufacturer Narrative
The customer did not return the suspected device for evaluation.Therefore, an in-house testing was performed with the in-house contour® next gen meter (serial # (b)(6)), in-house contour® next test strips (lot # 4dhe05v) and in-house contour® next control solution (lot # 4bv2g30) in five replicates.All tests recovered within the expected control range of 115 mg/dl to 144 mg/dl.The control results obtained with the in-house testing were properly marked as control tests in the meter.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
CONTOUR® NEXT
Common Device Name
QUALITY CONTROL MATERIAL
Manufacturer (Section D)
ASCENSIA DIABETES CARE US INC.
100 summit lake drive
valhalla NY 10595
Manufacturer (Section G)
BIONOSTICS, INC. BUSINESS TRADE NAME: RNA MEDICAL
registration number: 1220649
7 jackson rd.
devens MA 01434
Manufacturer Contact
shweta gulati
100 summit lake drive
valhalla, NY 10595
9142361830
MDR Report Key23038435
Report Number1810909-2025-00140
Device Sequence Number9889386
Product Code JJX
UDI-Device Identifier10301937314015
UDI-Public(01)10301937314015(17)251231(10)4BV2G30
Combination Product (Y/N)N
Initial Reporter CountryUS
PMA/510(K) Number
K151742
Number of Events Summarized1
Summary Report (Y/N)N
Serviced by Third Party (Y/N)Unknown
Reporter Type Manufacturer
Report Source Consumer
Initial Reporter Occupation Other
Type of Report Initial,Followup
Report Date (Section B) 11/14/2025
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Lay User/Patient
Device Expiration Date12/31/2025
Device Model Number7314
Device Catalogue Number83624818
Device Lot Number4BV2G30
Was Device Available for Evaluation? No
Is the Reporter a Health Professional? No
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 08/26/2025
Supplement Date Received by Manufacturer10/29/2025
Initial Report FDA Received Date09/12/2025
Supplement Report FDA Received Date11/14/2025
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured06/01/2024
Is the Device Labeled for Single Use? (Y/N) No
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Reuse
Patient Sequence Number1
Patient SexFemale
-
-